Pioppino

Metadata

Regulatory Status

European Union

• Food status: C. aegerita has a long history of consumption as a culinary mushroom in Italy, southern France, Spain, and other Mediterranean countries. It is not classified as a novel food when sold as a whole mushroom for culinary use.
• Concentrated extracts: Concentrated or standardized extracts intended for medicinal claims would likely require novel food authorization, as these forms lack a history of significant consumption before May 1997.
• Cultivation: Commercially cultivated at scale in Europe, particularly in Italy, where it is one of the most popular cultivated specialty mushrooms.

United States

• Dietary supplement: Not widely marketed as a medicinal supplement. Sold primarily as a gourmet culinary mushroom.
• FDA GRAS status: No specific GRAS determination for extracts or bioactive fractions.

China and Japan

• China: Recognized as an edible mushroom with traditional folk medicinal use for antimicrobial effects and improvement of nephritis and edema. Not listed in the Chinese Pharmacopoeia as a medicinal substance.
• Japan: Known as Yanagi-matsutake. Available as a culinary mushroom; not recognized in the Japanese Pharmacopoeia or as an approved health food ingredient.

Traditional European Use

• In southern Europe, particularly Italy, C. aegerita has been harvested from poplar, willow, and elm trees for centuries. It is among the oldest cultivated mushrooms in Europe, with cultivation records dating to Roman times and systematic cultivation documented since the early 19th century.
• Traditional folk medicinal uses include general tonic properties, antimicrobial application, and digestive support, though these are not well-documented in formal pharmacopoeias.

Conditions & Indications

Primary: Antioxidant and Antiaging (Preclinical Evidence)

• Antioxidant activity: Methanolic and water extracts of C. aegerita demonstrate significant free radical scavenging activity, including DPPH radical scavenging (up to 44.5% in some strains). Polysaccharides from both fruiting body and mycelium show dose-dependent antioxidant effects in vitro.
• Antiaging effects: In D-galactose-induced aging mouse models, C. aegerita polysaccharides (both water-extractable and enzymatic-extractable fractions) improved antioxidant enzyme activities (SOD, catalase, glutathione peroxidase), decreased lipid peroxidation (MDA levels), ameliorated lipid metabolism disorders, and provided organ protection. Enzymatic-extractable mycelium polysaccharides showed stronger antiaging effects than water-extractable fractions.

Secondary: Antitumor Activity (Preclinical Evidence)

• Ageritin-mediated cytotoxicity: Ageritin cleaves a single phosphodiester bond within the universally conserved alpha-sarcin loop (SRL) of 23—28S ribosomal RNA, inhibiting protein biosynthesis and inducing apoptosis. This mechanism shows selective cytotoxicity against tumor cells, with potential applications as an antitumor agent. Ageritin represents the prototype of a novel family of ribotoxin-like proteins found specifically in edible mushrooms.
• Polysaccharide-mediated tumor suppression: Crude polysaccharides from C. aegerita significantly inhibited transplanted sarcoma S180 and S180 ascites tumors in mice, suggesting immunomodulatory rather than directly cytotoxic antitumor activity.

Emerging: Anti-inflammatory, Antimicrobial, and Neuroprotective (Preclinical)

• Anti-inflammatory activity: Indole derivatives and phenolic compounds from C. aegerita demonstrate anti-inflammatory properties in vitro.
• Antimicrobial activity: Agrocybenine and cylindracin exhibit antifungal properties. Cylindracin, a cysteine-rich protein, specifically inhibits the growth of filamentous fungi but not yeasts or bacteria.
• Terpenoid diversity: Novel terpenoids isolated from fermentation broth of C. aegerita show diverse biological activities, though structure-activity relationships are still being characterized.

Mechanism of Action

Primary Mechanisms

1. Ageritin ribosomal RNA cleavage: Ageritin is a specific ribonuclease that cleaves rRNA at the alpha-sarcin/ricin loop (SRL), a universally conserved structure essential for ribosomal translocation during protein synthesis. This mechanism — shared with ricin and alpha-sarcin but executed by a structurally distinct protein — inhibits the elongation step of translation, leading to protein synthesis arrest and apoptosis. The selectivity for tumor cells over normal cells in vitro suggests differential uptake or sensitivity, though the molecular basis for this selectivity is not fully characterized.

2. Polysaccharide antioxidant and immunomodulatory activity: Beta-glucans and heteroglycans from C. aegerita scavenge reactive oxygen species and upregulate endogenous antioxidant defenses (SOD, catalase, glutathione peroxidase). The polysaccharides also modulate immune function through macrophage activation, consistent with the beta-glucan/dectin-1 signaling pathway common to medicinal mushrooms.

3. Lectin-mediated bioactivity: C. aegerita produces lectins (carbohydrate-binding proteins) with demonstrated antiproliferative activity in vitro. Mushroom lectins can induce apoptosis in cancer cell lines through binding to cell surface glycans and triggering intracellular signaling cascades.

Secondary Mechanisms

• Indole derivative free radical scavenging: Indole compounds contribute to antioxidant capacity through direct radical scavenging and may exert antiviral, anti-inflammatory, and anticancer effects through multiple molecular targets.
• Phenolic compound antioxidant activity: Phenolic metabolites contribute to the overall antioxidant capacity through hydrogen atom transfer and electron donation mechanisms.
• Sesquiterpene bioactivity: Cylindrin/cylindan and related sesquiterpenes demonstrate anticancer properties in vitro, though specific molecular targets are not yet fully defined.

Clinical Evidence Summary

No human clinical trials have been published for Cyclocybe aegerita for any therapeutic indication. All evidence is derived from in vitro studies and animal models.

Preclinical Evidence (Selected)

Evidence Limitations

• No human clinical trials have been published for any therapeutic indication.
• All antitumor evidence is from in vitro cell line studies or transplanted tumor models in mice. Translation to human cancer therapy is highly uncertain.
• Antiaging evidence is based solely on the D-galactose-induced aging mouse model, which has significant limitations as a model for human aging.
• Ageritin is a protein that would likely be degraded during digestion if consumed orally; its bioavailability from oral mushroom consumption is unknown, and its clinical relevance may be limited to parenteral or topical applications.
• Bioactive compound concentrations vary significantly between wild and cultivated specimens and between different cultivation substrates.
• The species has undergone recent taxonomic reclassification, and older literature under Agrocybe aegerita or A. cylindracea may include data from related but distinct Asian species.

Safety Profile

General Assessment

C. aegerita has centuries of culinary use in Europe with no documented history of toxicity when consumed as a food mushroom. It is one of the most widely cultivated specialty mushrooms in southern Europe. No systematic safety studies of concentrated extracts have been published.

Contraindications

• Mushroom allergy: Individuals with known allergy to Strophariaceae or related basidiomycete families should exercise caution.
• Immunocompromised patients: As with other beta-glucan-containing mushrooms, theoretical concern exists for immunomodulatory effects in immunocompromised individuals, though no specific evidence of harm exists for C. aegerita.

Drug Interactions

• No documented drug interactions. The absence of documented interactions reflects the lack of clinical studies rather than demonstrated safety.

Side Effects

• Common: None documented at culinary consumption levels.
• Uncommon: Allergic reactions possible in fungal-sensitive individuals.
• Theoretical: Ageritin’s ribosomal RNA-cleaving activity raises theoretical toxicological questions at high concentrations, though the protein is present in the edible fruiting body consumed safely for centuries and is presumably degraded during cooking and digestion.

Quality Concerns

• Wild specimens should be identified by experienced foragers, as confusion with toxic species is possible.
• Cultivation on contaminated substrates may introduce heavy metals or other contaminants; source verification is advisable.
• Taxonomic confusion between European C. aegerita and Asian species (particularly the C. chaxingu complex) may affect product identity in international trade.

Clinical Dosage

No Established Clinical Dosage

No human clinical trials have been conducted, so no evidence-based dosage recommendations exist for C. aegerita as a therapeutic agent.

Culinary Consumption

• Typical serving: 100—200 g fresh mushroom per meal, as a food
• Nutritional profile: Rich in protein (relative to other mushrooms), B vitamins, minerals (potassium, phosphorus), and dietary fiber
• Preparation: Typically sauteed, grilled, or used in pasta and risotto in Italian cuisine; cooking likely degrades ageritin and other proteins while preserving polysaccharide and phenolic content

Research Dosages (Animal Studies, Not for Human Extrapolation)

• Polysaccharide extracts: 100—400 mg/kg body weight in mouse antiaging studies (Jing et al. 2018)
• Note: These preclinical doses cannot be directly translated to human dosing without pharmacokinetic bridging studies

Extract Considerations

• Hot-water extraction captures polysaccharides and some phenolic compounds
• Ethanol extraction captures indole derivatives and sesquiterpenes
• Ageritin, being a protein, is best preserved in fresh or gently processed preparations but would likely be degraded by hot-water extraction or cooking

Sources

• Landi N, Clemente A, Pedone PV, Ragucci S, Di Maro A. Ageritin from pioppino mushroom: the prototype of ribotoxin-like proteins, a novel family of specific ribonucleases in edible mushrooms. Toxins. 2021;13(4):263
• Jing Y, Zhu J, Liu T, Bi S, Hu X, Chen Z, et al. Polysaccharides with antioxidative and antiaging activities from enzymatic-extractable mycelium by Agrocybe aegerita (Brig.) Sing. Evid Based Complement Alternat Med. 2018;2018:1584647
• Lo YC, Lin SY, Ulziijargal E, Chen SY, Chien RC, Tzou YJ, et al. Health-beneficial qualities of the edible mushroom, Agrocybe aegerita. Food Chem. 2008;108(1):97-108
• Erjavec J, Kos J, Ravnikar M, Dreo T, Sabotic J. Cylindracin, a Cys-rich protein expressed in the fruiting body of Cyclocybe cylindracea, inhibits growth of filamentous fungi but not yeasts or bacteria. Environ Microbiol. 2024;26(11):e16714
• Vizzini A, Angelini C, Ercole E. Le sezioni Velatae e Volvatae di Agrocybe sottogenere Aporus: rivalutazione del genere Cyclocybe Velen. ed una nuova specie. Riv Micol. 2014;57:259-278
• Ferraris L, Ferro S, Ferraris M. New terpenoids from the fermentation broth of the edible mushroom Cyclocybe aegerita. J Nat Prod. 2019;82(6):1543-1549
• Barros L, Cruz T, Baptista P, Estevinho LM, Ferreira ICFR. Wild and commercial mushrooms as source of nutrients and nutraceuticals. Food Chem Toxicol. 2008;46(8):2742-2747
• Zervakis GI, Ntougias S, Gargano ML, Besi MI, Polemis E, Typas MA, et al. A reappraisal of the Agrocybe aegerita/cylindracea complex through multilocus phylogeny. Fungal Divers. 2014;67:1-10
• Diyabalanage T, Mulabagal V, Mills G, DeWitt DL, Nair MG. Health-beneficial qualities of the edible mushroom, Agrocybe aegerita. Food Chem. 2008;108(1):97-108

Connections

• Shiitake (Lentinula edodes): Shiitake shares the beta-glucan-driven immunomodulatory and antitumor mechanisms common to culinary-medicinal mushrooms. Both species bridge the culinary and medicinal mushroom categories, with shiitake having substantially more clinical evidence.
• Oyster Mushroom (Pleurotus ostreatus): Oyster Mushroom is another widely cultivated culinary mushroom with demonstrated antioxidant and immunomodulatory properties from polysaccharides and phenolic compounds, making it a comparable species for the antioxidant-longevity category.
• Enokitake (Flammulina velutipes): Enokitake is a fellow wood-decomposing culinary mushroom with similar cultivation characteristics and polysaccharide-driven bioactivity, including the flammulin protein with antitumor properties that parallel ageritin’s mechanism.
• Maitake (Grifola frondosa): Maitake represents a more clinically advanced culinary-medicinal mushroom with beta-glucan immune modulation (D-fraction) that provides context for the potential development of C. aegerita polysaccharide research.
• Tremella (Tremella fuciformis): Tremella polysaccharides share antiaging properties demonstrated in similar D-galactose aging mouse models, providing a parallel for the antiaging evidence base of C. aegerita.